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Abstract
Purpose To explore the role of vacuum assisted closure (VAC) therapy versus conventional dressings in the Fournier’s 
gangrene wound therapy.
Patients and Methods This is a retrospective multi-institutional cohort study. Data of 92 patients from nine centers between 
2007 and 2018 were retrospectively analyzed. After surgery, patient having a local or a disseminated FG were managed with 
VAC therapy or with conventional dressings. The 10-weeks wound closure cumulative rate and OS were analyzed.
Results Of the 92 patients, 62 (67.4%) showed local and 30 (32.6%) a disseminated FG. After surgery, 19 patients (20.7%) 
with local and 14 (15.2%) with disseminated FG underwent to VAC therapy; 43 (46.7%) with local and 16 (17.4%) with 
disseminated FG were treated using conventional dressings. The multivariable logistic regression analysis demonstrated 
that the VAC in patients with disseminated FG led to a higher cumulative rate of wound closure than patients treated with 
no-VAC (OR = 6.5; 95% CI 1.1–37.4, p = 0.036). The Kaplan–Meier survival curves for the OS showed a significant differ-
ence between no-VAC patients with local and disseminated FG (OS rate at 90 days 0.90, 95% CI 0.71–0.97 vs 0.55, 95% 
CI 0.24–0.78, respectively; p = 0.039). Cox regression confirmed that no-VAC patients with disseminated FG showed the 
lowest OS (hazard ratio adjusted for sex and age HR = 3.4, 95% CI 1.1–10.4; p = 0.033).
Conclusions In this large cohort study, VAC therapy in patients with disseminated FG may offer an advantage in terms of 
10-weeks wound closure cumulative rate and OS at 90 days after initial surgery.
Keywords Fournier’s gangrene · Necrotizing fasciitis · Vacuum-assisted closure therapy · VAC · Wound therapy · Overall 
survival
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Introduction
Since its first description in 1883, Fournier’s gangrene 
(FG) has been defined as an aggressive necrotizing fascii-
tis affecting the perineal, perianal or genital areas, charac-
terized by an acute onset, a rapid progression, potentially 
fatal outcomes and a high mortality rate of 20–30% [1–5]. 
A polymicrobial aetiology has been recognized and inten-
tional or accidental trauma has been proposed as a possible 
source of infection [6, 7]. In addition, several predispos-
ing factors such as diabetes, chronic alcoholism, human 
immunodeficiency virus, chronic steroid abuse, cytotoxic 
drugs, lympho-proliferative disease, malnutrition and 
lower socio-economic status have been associated with 
the occurrence of FG [8, 9].
Following the European Association of Urology 
(EAU) guidelines on Urological Infections [10], the ini-
tial approach must be an aggressive, complete and early 
(< 24 h) surgical debridement of the necrotic tissue, as 
delayed and/or inadequate surgery may result in higher 
mortality. Immediate empiric parenteral antibiotic treat-
ment should be given; this can then be refined, guided 
by microbiological culture [8, 10]. Usually, repeated 
debridement is necessary leading to complex wound clo-
sure that requires frequent dressing and may need flaps or 
skin grafts [10]. Different protocols have been reported 
for postoperative open wound care, but their efficacy has 
not been properly analyzed and shows a very low level 
of evidence in the current guidelines [10]. Lack of evi-
dence regarding the role of vacuum-assisted closure (VAC) 
therapy in FG (level of evidence 4) [10] led us to explore 
its role in this rare niche of patients.
Therefore, the aim of our retrospective analysis was to 
assess with a hypothesis-generating and exploratory pur-
pose the possible role of VAC versus conventional dress-
ings in the wound therapy of FG in terms of cumulative 
rate of wound closure and overall survival (OS).
Patients and methods
Data of 92 patients admitted for FG in the emergency 
departments of nine Italian Hospitals between March 
2007 and June 2018 were retrospectively collected. All 
the patients received surgical treatment soon after the FG 
was diagnosed by the evidence of a necrotizing fasciitis 
involving the perineum, perianal region and/or the external 
genitalia [10].
The observed clinical and pathophysiologic patients’ 
characteristics were the following: gender, age, predispos-
ing factors, origin of FG, blood results on admission, FG 
extension, causative pathogens, urinary or fecal diversion, 
complications, length of hospital stay (LOS), type and 
number of surgical procedures, use of VAC or conven-
tional dressing, time from initial debridement to wound 
closure. According to Ozturk et al. on the base of the FG 
extension, patients were classified as having a local lesion 
confined to the perineum and/or pubic regions or a dis-
seminated lesion extended out of the perineum and/or 
pubic regions, i.e., abdomen, lumbar region or legs [11].
All patients had a multimodal approach, which included 
hemodynamic stabilization, surgical debridement and 
empiric antimicrobial therapy at admission (< 12 h). After 
debridement, conventional antiseptic dressings were used 
to cover the wounds (no-VAC group). Hydrogen peroxide 
and povidone/iodine solution were mostly used to soak the 
dressings. As no standardized procedure has been previously 
described, conventional dressing depended on the single 
center experience. Although different antiseptic solutions 
were used, all the centers continued by washing repeatedly 
with saline until healthy granulation tissue was formed. 
Wound dressings were changed daily in all cases. When 
available in the hospital, VAC was used on the base of sur-
geon clinical judgement right after the surgical debridement 
(VAC Group). VAC was applied at 75–125 mmHg, with 
5 min of suction followed by 2 min of rest, from the applica-
tion until the next dressing change. For each VAC change, 
wounds were serially debrided under anesthesia in the oper-
ating room until healthy and viable tissue was visible. These 
data were not achievable for the no-VAC group given the 
not standardized and large heterogeneity of dressing pro-
cedures. We considered patients who were allowed to heal 
by secondary or tertiary (VAC-mediated) intention. All the 
patients who underwent reconstructive surgery (split thick-
ness skin graft reconstruction, rotational flap reconstruction) 
were excluded from the retrospective analysis.
Statistical analysis
Categorical variables were summarized by absolute and 
relative percentage frequencies and were compared across 
independent groups by the Fisher’s exact test. Numerical 
variables were summarized by median and interquartile 
range (IQR) and were compared across independent groups 
by the Wilcoxon rank sum test.
Wound closure, defined as the complete re-epitheliali-
zation of the wound surface with no discernable exudate 
and without drainage or dressing, was investigated in the 
four treatment groups using cumulative incidence func-
tions (CIFs). Ten weeks was chosen as a reference time for 
assessing wound closure arbitrarily given the unavailability 
of standardized benchmarks. The 10-week wound closure 
cumulative rate was compared between groups by Fisher’s 
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exact test and by multivariable logistic regression (with gen-
der and age as potential confounders).
Overall survival (OS) was defined as the time elapsed 
from the date of admission to the date of death from any 
cause or the date of last follow-up. OS was compared 
between groups using Kaplan–Meier survival estimates, the 
log-rank test, and the proportional-hazards Cox regression 
model.
All the statistical tests were two-sided and a p value of 
less than 0.05 was considered statistically significant. All 
estimations were performed using Stata 15 (StataCorp 2017, 
College Station, TX) and R 3.6.1 (R Foundation for Statisti-
cal Computing, Vienna, Austria) software.
Results
Of the 92 patients, 62 (67.4%) showed local FG and 30 
(32.6%) a disseminated condition. The patients’ character-
istics and demographic have been listed in Table 1 accord-
ing to the extension of disease and by VAC or no-VAC 
treatment. Of all patients, 89 (96.7%) were males. Several 
characteristics of patients with local and disseminated FG 
managed by VAC or no-VAC treatment were similar. Par-
ticularly, no statistically significant differences were found 
for the following variables (see Table 1): age, distribution of 
predisposing factors such as obesity (BMI ≥ 30), smoking, 
alcoholism, kidney failure, neurogenic bladder and pelvic 
radiotherapy and blood results such as C-reactive protein, 
neutrophil-to-lymphocyte ratio and procalcitonin. The 
Fournier Gangrene Severity Index (FGSI) was calculated 
in all the groups and did not show significant differences 
(p = 0.13). The most common origin of local FG was uro-
genital diseases whilst disseminated FG origin was mostly 
mixed urogenital and anorectal. A median number of two 
microorganisms was isolated both in patients with local 
(IQR 1–3) and with disseminated FG (IQR 2–3) (p = 0.284). 
The frequency distribution of reported microorganisms in 
the two FG groups are shown in Fig. 1.
The most common microorganisms reported both in 
patients with local FG and with disseminated FG included: 
Escherichia coli, Enterococcus faecalis, Pseudomonas 
Table 1  Characteristics and demographic of patients with local and disseminated FG managed by VAC or no-VAC treatment
°No. pts (%)
n no. pts for which this data was recorded, M males
*p value refers to a median score comparison in case of continuos variables (Kruskal–Wallis equality-of-populations rank test) or to a proportion 
comparison of the four groups in case of binary variables (Fisher’s exact test)
Local FG Disseminated FG p value*
VAC group No-VAC group VAC group No-VAC group
Age, years (n = 92) 62 (54–75) 69 (58–76) 66.5 (58–72) 70 (60.5–82) 0.444
Gender, M (n = 92) 19 (100)° 43 (100) 12 (85.7) 15 (93.8) 0.027
Predisposing factors
 Obesity (n = 86) 6 (35.3) 8 (20) 1 (7.1) 3 (20) 0.316
 Diabetes mellitus type II (n = 92) 12 (63.2) 15 (34.9) 9 (64.3) 12 (75) 0.017
 Hypertension (n = 92) 12 (63.2) 19(44.2) 13 (92.9) 12 (75) 0.005
 Immobility (n = 92) 4 (21.1) 8 (18.6) 8 (57.1) 6 (37.5) 0.036
 Smoking (n = 87) 9 (50) 20 (51.3) 5 (35.7) 6 (37.5) 0.671
 Alcoholism (n = 84) 3 (16.7) 7(18.9) 3 (21.4) 6 (40) 0.393
 Kidney failure (n = 91) 7 (38.9) 9 (20.9) 2 (14.3) 3 (18.8) 0.376
 Neurogenic bladder (n = 91) 0 (0) 2 (4.7) 0 (0) 1 (6.3) 0.866
 Pelvic radiotherapy (n = 91) 2 (11.1) 0 (0) 0 (0) 0 (0) 0.089
Origin of Fournier’s Gangrene
 Anorectal (n = 83) 2 (10.5) 2 (5.1) 3 (30) 3 (20) 0.000
 Urogenital (n = 83) 14 (73.7) 28 (71.8) 1 (10) 2 (13.3)
 Mixed (anorectal + urogenital) (n = 83) 3 (15.8) 9 (23.1) 6 (60) 10 (66.7)
Blood results on admission
 C-reactive protein (mg/L) (n = 87) 138.7 (93.7–187.0) 63.7 (9.6–195.0) 192.6 (45.0–309.0) 47.2 (19.6–223.8) 0.154
 Neutrophil-to-lymphocyte ratio (n = 66) 14.4 (9.6–19.3) 12.1 (8.8–18.0) 12.3 (8.2–36.1) 16.1 (6.4–39.1) 0.791
 Procalcitonin (ng/mL) (n = 62) 0.8 (0.6–9.1) 2.3 (0.3–23.0) 22.0 (6.9–31.9) 10.8 (0.8–22.2) 0.140
 Albumin (g/dL) (n = 84) 3.0 (2.7–3.2) 2.8 (2.2–3.3) 2.6 (2.0–2.6) 2.3 (2.0–2.9) 0.008
 FGSI 3 (1–8) 3.6 (1–6) 2 (2–6) 3.7 (5–9) 0.135
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aeruginosa, Proteus mirabilis, Candida albicans, Klebsiella 
pneumoniae, Enterococcus faecium and Acinetobacter bau-
mannii as listed in Table 2. All the patients underwent surgi-
cal radical debridement within the first 12 h after admission. 
The different surgical approaches used for patients with local 
and disseminated FG are summarized in Table 2.
Following the initial debridement, 19 patients (20.7%) 
with local FG were managed with VAC therapy and 43 
(46.7%) were treated using conventional dressings. Among 
the disseminated FG patients, 14 (15.2%) were managed 
with VAC therapy both in genital and non-genital wounds 
and 16 (17.4%) were treated using conventional dress-
ings. After surgery, the VAC was changed both in the local 
(median 6 days; IQR 1–7) and in the disseminated FG 
group (median 3.5 days; IQR 2–9). The median LOS was 
significantly longer for patients with local and disseminated 
FG in the VAC group (28 days, IQR 16–51, and 39 days, 
IQR 28–74, respectively) than in no-VAC group (18 days, 
IQR 12–26, and 30 days, IQR 16.5–66.5, respectively) 
(p = 0.006).
Major complications (i.e., sepsis, renal failure, acute res-
piratory distress syndrome, multiple organ failure) occurred 
both in patients with local FG (VAC group median 2.0, IQR 
1.5–4.0; no-VAC group median 2.0, IQR 0.0–3.0) and in 
those with a disseminated condition (VAC group median 
3.0, IQR 2.5–4.5; no-VAC group median 4.0, IQR 2.0–5.0) 
(p = 0.011). Overall mortality rate was 13/92 patients 
(14.1%). Follow-up in the entire cohort was 33 weeks, IQR 
19–61.
The median time from the initial debridement to the 
complete wound closure was longer in patients with local 
FG managed with VAC therapy (45 days, IQR 30–60) than 
in the no-VAC group (23 days, IQR 12–36) (p = 0.011). In 
patients with disseminated FG, the median time in the no-
VAC group (56 days, IQR 17–90.5) was longer than in VAC 
group (38.5 days, IQR 23–59.5) but the difference was not 
statistically significant (p = 0.671).
Ten weeks after the initial debridement, the wound clo-
sure occurred in 14 patients (73.7%) with local disease man-
aged with VAC and in 33 (89.2%) patients treated with no-
VAC approach (p = 0.247). In the group with disseminated 
disease, the wound closure was achieved in ten patients 
(71.4%) managed with VAC and in four (28.6%) treated with 
no-VAC approach (p = 0.057) (Fig. 2).
The multivariable logistic regression analysis of 10 weeks 
wound closure cumulative rate demonstrated that the VAC in 
patients with disseminated FG led to a higher rate of wound 
closure than no-VAC patients (odds ratio adjusted for sex 
Fig. 1  Relative frequency distribution for the number of microorganisms detected in patients with local and disseminated FG
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and age OR = 6.5; 95% CI 1.1–37.4, p = 0.036). Conversely, 
in patients with local FG, the 10-week wound closure cumu-
lative rate in no-VAC patients did not show significant dif-
ferences than in those managed with VAC therapy (adjusted 
OR = 0.24; 95% CI 0.05–1.14, p = 0.073). Moreover, the 
comparison between the effect of VAC in patients with local 
and disseminated FG (OR = 6.5 vs OR = 0.2, respectively) 
was statistically significant (p = 0.009). Finally, although 
type 2 diabetes and hypertension were significantly asso-
ciated with a reduction of the 10-weeks wound closure 
(respectively OR = 0.24; 95% CI 0.07–0.78, p = 0.017 and 
OR = 0.12; 95% CI 0.02–0.58, p = 0.09), the estimated 
ORs did not significantly change after the addition of these 
pathologies to the multivariable model adjusted for sex and 
age.
Comparing the KM Kaplan–Meier survival curves for 
the OS, a significant difference between patients with local 
and disseminated FG was found when patients were treated 
with conventional dressings (OS rate at 90 days 0.90, 95% 
CI 0.71–0.97 vs 0.55, 95% CI 0.24–0.78, respectively; 
p = 0.039) (Fig. 3). Furthermore, Cox regression confirmed 
that patients with disseminated FG managed with the no-
VAC approach showed the lowest OS (hazard ratio adjusted 
for sex and age HR = 3.4, 95% CI 1.1–10.4; p = 0.033).
Discussion
FG is an obliterative endarteritis of the subcutaneous 
arteries resulting in gangrene of the overlying skin [11]. 
FG is aggressive, often life threatening and polymicrobial 
[8, 10]. In our analysis, independently from the exten-
sion, all the cases were sustained by a median number of 
two microorganisms at the same time, being Escherichia 
coli and Enterococcus faecalis the most common bacteria 
detected. Referring to the predisposing and demographic 
factors, our results are in line with the currently available 
literature [8, 10, 12] being the adult age or elderly age, 
diabetes and hypertension the most common ones.
Consensus from case series suggests that surgical 
debridement should be early and aggressive, as delayed 
and/or inadequate surgery may result in higher mortality 
[8, 10, 12]. Computed tomography or MRI can help define 
para-rectal involvement, suggesting the need for bowel 
diversion [8, 10]. In our study, the surgical debridement 
approach varied depending on the FG extension. Intui-
tively, more extensive abdominal surgery and bowel diver-
sions were more common in disseminated FG patients.
Following the initial debridement, wound manage-
ment is important. Yanaral et al. reported that most cases 
were managed with conventional dressings that contain a 
wide and not standardized variety of active agents such as 
saline, povidone iodine, potassium permanganate, Dakin’s 
solution, enzymatic agents for wound cleansing, or pol-
yhexanide [13]. The same authors retrospectively com-
pared 54 FG patients treated with VAC or conventional 
dressings reporting that VAC was effective offering fewer 
dressing changes, less pain, and greater mobility [13]. The 
role of VAC therapy has been furtherly investigated in sev-
eral case series. Mallikarjuna et al. [2] described that VAC 
works by exposing a wound to subatmospheric pressure for 
an extended period increasing blood supply, migration of 
inflammatory cells and the formation of granulation tissue 
compared with traditional dressing [8, 14].
Patients undergoing VAC reported longer durations 
of hospital stay in some studies [15–17], although some 
authors described opposite data [18, 19]. Yanaral et al. 
suggested that soft-tissue defects extension may impact the 
LOS which can be exacerbated by sepsis-induced compli-
cations or large soft-tissue defects extending [20]. Yücel 
et al. retrospectively analyzed 25 FG patients underlining 
how the use of VAC is likely associated with the increased 
complexity of the lesion [15]. Hence, most of the available 
literature reports that VAC is effective in the management 
of large wounds with less pain, a lower patient discomfort 
and number of dressings and a greater mobility [13–21]. 
Furthermore, given the rarity of this clinical condition, all 
Table 2  Detected microorganisms and surgical approaches used in 
patients with local and disseminated FG
° No. pts (%)
Local FG° Disseminated FG°
Number of patients 62 30
Detected microorganisms
 Escherichia coli 35 (56.5) 14 (46.7)
 Enterococcus faecalis 18 (29) 12 (40)
 Pseudomonas aeruginosa 13 (21) 12 (40)
 Proteus mirabilis 10 (16.1) 2 (6.7)
 Candida albicans 9 (14.5) 4 (13.3)
 Klebsiella pneumoniae 8 (12.9) 4 (13.3)
 Enterococcus faecium 6 (9.7) 6 (20)
 Acinetobacter baumannii 4 (6.5) 3 (10)
Surgical approaches
 Scrotal surgery 55 (88.7) 17 (56.7)
 Monolateral orchiectomy 17 (27.4) 2 (6.7)
 Bilateral orchiectomy 5 (8.1) 2 (6.7)
 Funiculectomy 11 (17.7) 1 (3.3)
 Perineal surgery 16 (25.8) 14 (46.7)
 Inguinal surgery 3 (4.8) 2 (6.7)
 Abdominal surgery 5 (16.7)
 Penile amputation 1 (1.6)
 Colostomy 6 (9.7) 14 (46.7)
 Ileostomy 3 (10)
 Suprapubic cystostomy 2 (3.2) 6 (20)
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Fig. 2  Time trends of wound closure cumulative rates in patients with local and disseminated FG managed with VAC or no-VAC therapy
Fig. 3  Kaplan–Meier survival 
curves for the overall survival of 
patients with local and dissemi-
nated FG managed with VAC or 
no-VAC therapy
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the studies available about FG are retrospective and with 
small cohorts leading to low level evidence papers.
Alternative and/or complementary approach to VAC 
have been proposed. The role of hyperbaric oxygen (HBO) 
therapy remains controversial. Beneficial effects of HBO 
such as an increase in oxygen tension in the infected area 
have been reported [22–24] in very small case series ame-
liorating the tissue oxygenation [23]. However, HBO is an 
expensive treatment option without any described improve-
ment in prognosis [25]. Therefore, Wagner et al. suggested 
an aggressive multimodality therapy based on surgery, anti-
biotics and VAC could be crucial where other approaches 
such as HBO may be more expensive and not so helpful [26]. 
VAC has been criticized to be expensive [27], Ozturk et al. 
performed a cost analysis reporting that the cost for treat-
ing five FG patients with VAC was $8,850 versus $8,800 
for conventional treatment of five similar patients [11]. 
Although there were not significant differences in the costs, 
this was just a preliminary and not accurate estimation. Fur-
thermore, health care systems are very different for each 
country and cost-analysis studies are mandatory.
Given these considerations, this multi-institutional obser-
vational study aimed to explore the possible role of VAC 
therapy versus conventional dressings in FG in terms of 
cumulative rate of wound closure and OS. Moreover, we 
analyzed a large cohort of FG cases collecting a wide spec-
trum of data concerning: predisposing factors, admission 
blood results, FG origin and extension, pathogens, urinary 
or fecal diversion, complications, LOS, type and number of 
surgical procedures, use of VAC or conventional dressing, 
time from initial debridement to wound closure. In our study, 
of 92 FG patients, 33 were treated with VAC (19 with local 
and 14 with disseminated disease) and 59 were treated with 
conventional approach (43 with local and 16 with dissemi-
nated disease). We considered secondary or tertiary (VAC-
mediated) intention healings without reconstruction.
Within the nine centers, no-VAC therapy (otherwise 
called conventional [13, 14]) had not a standardized protocol 
leading to the use of different antiseptic solutions in slightly 
but actually different manners. This limit should be stated 
given its alignment with the heterogeneity of the conven-
tional therapy in the literature [13, 14]. According to other 
papers [14–16], our results showed that VAC therapy is asso-
ciated with a longer LOS both in local and disseminated FG.
Although the results on the time to complete wound 
closure did not show a significant difference between dis-
seminated cases treated either with VAC or with the no-VAC 
approach, patients with a local disease reported a signifi-
cantly longer recovery when managed with the VAC therapy. 
Nevertheless, in patients with disseminated disease treated 
with VAC we observed significant differences regarding the 
wound closure rate that may suggest an advantage in the use 
of this technique.
Ten weeks was chosen as a reference time for assess-
ing wound closure arbitrarily given that two-thirds (61/92, 
66.3%) of the patients reported a tertiary wound closure at 
10 weeks. Regarding the cumulative rate of wound closure, 
the results at 10 weeks after surgery did not show a sta-
tistically significant difference in the local FG group once 
treated with or without VAC. Conversely, the multivariable 
logistic regression analysis of 10-weeks wound closure 
cumulative rate showed that the disseminated FG patients 
treated with VAC had a higher percentage of wound closure 
(p = 0.036). Furthermore, comparing the KM Kaplan–Meier 
survival curves for the OS, a significant difference between 
patients with local and disseminated FG was found when 
patients were treated with conventional dressings (OS rate at 
90 days 0.90, 95% CI 0.71–0.97 vs 0.55, 95% CI 0.24–0.78, 
respectively; p = 0.039) and the Cox proportional hazard 
regression model highlighted that patients with disseminated 
FG managed with the no-VAC approach showed the low-
est inter-group OS. Thus, our study suggests that VAC may 
offer an advantage in terms of wound closure at 10 weeks, 
especially for disseminated cases of FG where an aggressive 
multimodality approach can be crucial; these patients also 
have the lowest OS when not treated with VAC, suggesting 
its possible role in OS.
As we stated above, our purpose was to investigate the 
role of VAC in the multimodal approach for the FG in a 
hypothesis-generating framework. In other words, given 
the retrospective design of our study and the relatively 
small sample size, conclusions cannot be definitive on the 
role of VAC therapy on local or disseminated FG patients. 
Although this is not a prospective trial, the retrospective 
analysis brought out some elements that seemed to sug-
gest an advantage in the VAC use in disseminated forms of 
disease in terms of faster recovery and a better OS. These 
data seem to suggest that in a patient presenting with a dis-
seminated FG disease, VAC therapy may offer an advantage 
in the context of a multimodal approach. However, given 
the observational retrospective design of this study and its 
limited number of patients, we could not provide a decision-
making algorithm. Anyhow, defining a clear algorithm was 
not our endpoint; this aim could be adequately addressed 
only by a hypothesis-testing randomized clinical trial pow-
ered with a proper sample size.
Although these results seemed to be encouraging, the 
limits of the study need to be carefully taken into account. 
We reviewed 92 patients and a wide set of variables with 
a hypothesis-generating and exploratory purpose. This 
retrospective design did not allow to perform a controlled 
treatment allocation, and this led to multiple and unavoid-
able biases (e.g., selection, information). The sample size is 
limited to 92 cases that are a relatively large sample for this 
rare pathology, but from a statistical point of view, they can 
represent a limit to the analysis. A prospective randomized 
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well powered clinical study will help to better clarify the 
role of VAC in this niche of patients. Unfortunately, prospec-
tively accrue and randomize patients is also difficult since 
this is typically an emergency situation and does not allow 
for detailed, thorough anamnesis and enrolling in a trial.
Conclusions
In patients with disseminated FG, VAC may offer an advan-
tage in terms of 10-week wound closure cumulative rate and 
OS at 90 days after initial surgery. On the contrary, local FG 
patients did not show the same advantages.
These results in the use of VAC in FG need to be sup-
ported by a large randomized controlled trial.
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